The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.


This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
20 December 2021

“Darnitsa” has been included in TOP-25 of the smartest companies in Ukraine according to Forbes

20 December 2021

Forbes magazine, one of the world`s most respected financial and economic publications, included pharmaceutical company “Darnitsa” in its rating of the TOP-25 smartest businesses in Ukraine. The main criterion for inclusion in the ranking was the company`s effective Research&Development (R&D) processes responsible for research and development of new products.

R&D department of “Darnitsa” was established in 1993 and reached its full capacity in 2014. At that time, the company defined strategic directions for manufacturing medicines. They were cardiology, neurology and pain management. About 80 specialists, whose achievements have been recognized by scientists from developed countries, are working on the development of new medicines.

In an Oxford University study, the anti-inflammatory medicine “Dexamethasone” proved to be effective in reducing the risk of mortality in critically ill patients suffering from COVID-19,” said the ranking authors.

“Dexamethasone-Darnitsa” is one of the company`s developments. In total, “Darnitsa” launched 50 brands on the market in 2015-2020.  The company`s medicines are sold in 16 countries. Headache tablets “Citramon-Darnitsa” are leaders in terms of export volume.

According to the Pharmaceuticals of Ukraine 2021 guide, the pharmaceutical industry is the most innovative in the country, generating more than 4% of GDP. This includes continuous R&D activities that significantly increase the added value of the final product at the development stage.

“In 2021, “Darnitsa” launched 21 new brands on the market, while in 2020 there were only 10 in comparison. Due to digital transformation and optimization of business processes, we have been able to accelerate the launch of new medicines from 30 to 18 months. It is extremely pleasant to be included into Forbes rating, it means that we are not only moving in the right direction, but our success is noticeable to the general public,” – said Irina Denyak, Director of Development of pharmaceutical company “Darnitsa”.

The TOP-25 list of the smartest companies of Ukraine was published in the December issue of Forbes magazine. According to the journalists, in order to study the R&D processes in Ukraine, they have surveyed about 150 companies. They selected the best 25 out of them.


PJSC Pharmaceutical Company “Darnitsa” was founded in 1930 and is celebrating its 91st anniversary this year. Since 1998, “Darnitsa” has been Ukraine’s leader in the production of medicines in volume terms. The strategic areas of portfolio development are cardiology, neurology and pain management. During 2015-2020, “Darnitsa” has launched 50 pharmaceutical brands on the market.

The information provided above is intended solely for publication in specialist publications for medical institutions and physicians, and for distribution at specialist seminars, conferences on medical topics.

Specialized edition for medical institutions and doctors.